In this issue:
Osteoporosis treatment in postmenopausal ER+ disease
The psychosocial outcomes of having CPM
Ribociclib + endocrine therapy improved PFS in MONALEESA-7
ABP 980 vs reference trastuzumab in HER2+ early disease
AZD9496 well tolerated in ER+/HER2− advanced disease
ASCO guideline update on HER2+ advanced disease and brain metastases
ASCO guidelne update on systemic therapy for HER2+ advanced disease
Taselisib + fulvestrant active in HER2–, hormone receptor+ advanced disease
21-gene RS assay predicts benefit of PMRT for OS
Fulvestrant in postmenopausal hormone receptor+ advanced disease
The LUM Imaging System rapidly assesses lumpectomy cavities
Please login below to download this issue (PDF)